Proportion and risk indicators of nonadherence to antihypertensive therapy: A meta-analysis

Patient Preference and Adherence

Volumn 8, Issue , 2014, Pages 211-218

  Lemstra, Mark ^a   Alsabbagh, M Wasem ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Adherence; Antihypertensives; Meta analysis

Indexed keywords

EID: 84894233073     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S55382     Document Type: Article

References (51)

1. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Geneva: WHO; 2003.
2. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
3. Haynes RB, Yao X, Degani A, Kripalani S, Garg A, McDonald HP. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2005:CD000011.
4. Cutler DM, Everett W. Thinking outside the pillbox - medication adherence as a priority for health care reform. N Engl J Med. 2010;362:1553-1555.
5. Lemstra M, Blackburn DF, Crawley A, Fung R. Proportion and risk indicators of non-adherence to statin therapy: a meta-analysis. Can J Cardiol. 2012;28(5):574-580.
6. Eze-Niliam CM, Thombs BD, Lima BB, Smith CG, Ziegelstein RC. The association of depression with adherence to antihypertensive medications: a systematic review. J Hypertension. 2010;28:1785-1795.
7. Kronish IM, Woodward M, Sergie Z, Ogedegbe G, Falzon L, Mann DM. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation. 2011;123:1611-1621.
8. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10:3-12.
9. Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective database studies - report of the ISPOR task force on retrospective databases. Value Health. 2003;6:90-97.
10. Alsabbagh W, Lemstra M, Eurich D, et al. Socioeconomic Status and Non Adherence to Anti-Hypertensive Drugs: A Systematic Review and Meta-Analysis. Value in Health. 2014. Available from: http://www.ispor.org/publications/value/articlesinpress.asp. Accessed February 4, 2014.
11. Douglas, GA. Practical Statistics for Medical Research. 1st ed. New York: Chapman and Hall; 1991.
12. Fleiss JI. The statistical basis of meta-analysis. Stat Methods Med Res. 1993;2:121-145.
13. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11:193-206.
14. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons; 2006.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
16. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177-186.
17. Setoguchi S, Choudhry NK, Levin R, Shrank WH, Winkelmayer WC. Temporal trends in adherence to cardiovascular medications in elderly patients after hospitalization for heart failure. Clin Pharmacol Ther. 2010;88:548-554.
18. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens. 1997;10:697-704.
19. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998;20:671-681.
20. Degli Esposti L, Degli Esposti E, Valpiani G, et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther. 2002;24:1347-1357; discussion 1346.
21. Yang Y, Thumula V, Pace PF, Banahan BF 3rd, Wilkin NE, Lobb WB. Predictors of medication nonadherence among patients with diabetes in Medicare part D programs: a retrospective cohort study. Clin Ther. 2009;31:2178-2188; discussion 2150-2151.
22. Shaya FT, Du D, Gbarayor CM, Frech-Tamas F, Lau H, Weir MR. Predictors of compliance with antihypertensive therapy in a high-risk Medicaid population. J Natl Med Assoc. 2009;101:34-39.
23. Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med. 2007;20:72-80.
24. Perreault S, Lamarre D, Blais L, et al. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother. 2005;39:1401-1408.
25. Taira DA, Gelber RP, Davis J, Gronley K, Chung RS, Seto TB. Antihypertensive adherence and drug class among Asian Pacific Americans. Ethn Health. 2007;12:265-281.
26. van Wijk BL, Shrank WH, Klungel OH, Schneeweiss S, Brookhart MA, Avorn J. A cross-national study of the persistence of antihypertensive medication use in the elderly. J Hypertens. 2008; 26:145-153.
27. Lamb D, Eurich D, McAlister F, et al. Changes in adherence to evidence-based medications in the first year after initial hospitalization for heart failure: observational cohort study from 1994 to 2003. Circ Cardiovasc Qual Outcomes. 2009;2:228-235.
28. Gogovor A, Dragomir A, Savoie M, Perreault S. Comparison of persistence rates with angiotensin-converting enzyme inhibitors used in secondary and primary prevention of cardiovascular disease. Value Health. 2007;10:431-441.
29. Siegel D, Lopez J, Meier J. Antihypertensive medication adherence in the Department of Veterans Affairs. Am J Med. 2007;120:26-32.
30. Friedman O, McAlister FA, Yun L, Campbell NR, Tu K. Antihypertensive drug persistence and compliance among newly treated elderly hypertensives in Ontario. Am J Med. 2010;123:173-181.
31. Corrao G, Zambon A, Parodi A, et al. Do socioeconomic disparities affect accessing and keeping antihypertensive drug therapy? Evidence from an Italian population-based study. J Hum Hypertens. 2009;23:238-244.
32. Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med. 2004;117: 73-81.
33. Wogen J, Kreilick CA, Livornese RC, Yokoyama K, Frech F. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm. 2009;9:424-429.
34. Yang Y, Thumula V, Pace PF, Banahan BF 3rd, Wilkin NE, Lobb WB. Nonadherence to angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare part D programs. J Am Pharm Assoc. 2010;50:527-531.
35. Kramer JM, Hammill B, Anstrom KJ, et al. National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J. 2006;152:454. e1-e8.
36. Degli Esposti E, Sturani A, Di Martino M, et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens. 2002;16:439-444.
37. Wong MC, Jiang JY, Su X, Wang H, Tang JL, Griffiths SM. Individuals at risk of beta-blocker discontinuation: a cohort study in 19,177 Chinese patients. Clin Res Cardiol. 2010;99:277-284.
38. Sung SK, Lee SG, Lee KS, Kim DS, Kim KH, Kim KY. First-year treatment adherence among outpatients initiating antihypertensive medication in Korea: results of a retrospective claims review. Clin Ther. 2009;31:1309-1320.
39. Evans CD, Eurich DT, Remillard AJ, Shevchuk YM, Blackburn D. First-fill medication discontinuations and nonadherence to antihypertensive therapy: an observational study. Am J Hypertens. 2012;25:195-203.
40. Rasmussen JN, Gislason GH, Rasmussen S, et al. Use of statins and beta-blockers after acute myocardial infarction according to income and education. J Epidemiol Community Health. 2007;61:1091-1097.
41. Carrao G, Parodi A, Zambon A, et al. Reduced discontinuation of antihypertensive therapy by two-drug combination as first step. Evidence from daily life practice. J Hypertens. 2010;28:1584-1590.
42. World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems. New York: WHO; 2008.
43. Evans CD, Eurich DT, Lu X, Remillard AJ, Shevchuk YM, Blackburn D. The association between market availability and adherence to antihypertensive medications: an observational study. Am J Hypertens. 2013;26:180-190.
44. Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialties: Thiazide Diuretics - Product Monograph. Ottawa: Canadian Pharmacists Association; 2012.
45. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: a meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101-2107.
46. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
47. O'Malley AS, Forrest CB, Mandelblatt J. Adherence of low-income women to cancer screening recommendations. J Gen Intern Med. 2002;17:144-154.
48. Celano M, Geller RJ, Phillips KM, Ziman R. Treatment adherence among low-income children with asthma. J Pediatr Psychol. 1998;23:345-349.
49. Orlandi MA. Promoting health and preventing disease in health care settings: an analysis of barriers. Prev Med. 1987;16:119-130.
50. Diamond J. Guns, Germs, and Steel: The Fates of Human Societies. New York: WW Norton; 1999.
51. US Census Bureau. People below poverty level and below 125 percent of poverty level by race and Hispanic origin: 1980 to 2009. 2012. Available from: http://www.census.gov/compendia/statab/2012/tables/12s0711.pdf. Accessed January 24, 2013.